IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.663
NA - Nord America 5.523
EU - Europa 1.777
SA - Sud America 741
AF - Africa 89
Continente sconosciuto - Info sul continente non disponibili 82
OC - Oceania 27
Totale 18.902
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 7.498
US - Stati Uniti d'America 5.263
CN - Cina 1.266
IT - Italia 895
HK - Hong Kong 821
BR - Brasile 469
BD - Bangladesh 346
VN - Vietnam 283
GB - Regno Unito 245
FR - Francia 208
DE - Germania 130
CA - Canada 113
IN - India 106
AR - Argentina 82
MX - Messico 69
ID - Indonesia 60
EC - Ecuador 51
CO - Colombia 49
NL - Olanda 45
FI - Finlandia 44
TR - Turchia 39
UA - Ucraina 32
ZA - Sudafrica 31
VE - Venezuela 29
CZ - Repubblica Ceca 28
PL - Polonia 28
MY - Malesia 26
PH - Filippine 26
AU - Australia 25
JP - Giappone 25
SA - Arabia Saudita 24
ES - Italia 22
PK - Pakistan 21
RU - Federazione Russa 19
CL - Cile 18
IQ - Iraq 17
CR - Costa Rica 16
PY - Paraguay 16
JM - Giamaica 12
SE - Svezia 12
HN - Honduras 11
NP - Nepal 11
PE - Perù 11
NI - Nicaragua 10
CH - Svizzera 9
EG - Egitto 9
TH - Thailandia 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
MA - Marocco 8
BO - Bolivia 7
TN - Tunisia 7
UY - Uruguay 7
TT - Trinidad e Tobago 6
AM - Armenia 5
BH - Bahrain 5
DZ - Algeria 5
ET - Etiopia 5
IE - Irlanda 5
IL - Israele 5
KE - Kenya 5
KZ - Kazakistan 5
LB - Libano 5
SV - El Salvador 5
AL - Albania 4
BE - Belgio 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
IR - Iran 4
KR - Corea 4
LT - Lituania 4
OM - Oman 4
SY - Repubblica araba siriana 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
AT - Austria 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CY - Cipro 3
DK - Danimarca 3
EE - Estonia 3
GT - Guatemala 3
HU - Ungheria 3
KH - Cambogia 3
KW - Kuwait 3
LU - Lussemburgo 3
MD - Moldavia 3
MN - Mongolia 3
PA - Panama 3
PR - Porto Rico 3
RO - Romania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
GY - Guiana 2
IS - Islanda 2
JO - Giordania 2
ME - Montenegro 2
PS - Palestinian Territory 2
Totale 18.792
Salva come PNG Salva come JPEG
Città #
Ashburn 1.189
San Jose 1.110
Hong Kong 806
Singapore 804
Rome 548
Hefei 392
Beijing 311
Council Bluffs 261
Boardman 217
Columbus 206
Dallas 196
Lauterbourg 172
London 159
Santa Clara 146
Shanghai 138
Phoenix 133
Los Angeles 99
Ho Chi Minh City 98
New York 85
Munich 62
Hanoi 55
San Francisco 51
São Paulo 51
Mexico City 45
Seattle 37
Toronto 29
Brno 28
Milan 28
Brasília 27
Pune 27
Turku 27
Guangzhou 26
Montreal 25
Amsterdam 24
Buffalo 24
Naples 23
Warsaw 23
Guayaquil 22
Rio de Janeiro 22
Tokyo 22
West Jordan 22
Washington 21
Bogotá 19
Denver 17
Helsinki 17
Atlanta 16
Chennai 16
Las Vegas 16
Orem 16
Boston 15
Brooklyn 15
Chicago 14
Haiphong 14
Charlotte 13
Da Nang 13
Canberra 12
Johannesburg 12
Quito 12
San José 12
Frankfurt am Main 11
Manchester 11
Queens 11
Riyadh 11
Sona 11
Bari 10
Bologna 10
Houston 10
Kuala Lumpur 10
Lahore 10
Paris 10
Stockholm 10
Caracas 9
Florence 9
Genoa 9
Managua 9
Philadelphia 9
Shenzhen 9
Buenos Aires 8
Curitiba 8
Jeddah 8
Kingston 8
Melbourne 8
New Delhi 8
Verona 8
Hangzhou 7
Hải Dương 7
Kyiv 7
Miami 7
Tashkent 7
Turin 7
Zhengzhou 7
Belém 6
Biên Hòa 6
Cleveland 6
Istanbul 6
Lima 6
Medellín 6
Mumbai 6
Pasadena 6
Porto Alegre 6
Totale 8.378
Salva come PNG Salva come JPEG
Nome #
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 271
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 264
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 259
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 254
Advances in management of periprosthetic joint infections: an historical prospective study 250
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 245
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 244
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 240
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 240
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 240
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 237
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 236
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 231
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 230
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 229
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 228
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 224
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 223
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 222
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 222
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 216
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 215
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 214
Assessment of liver function by the exhaled breath-print during chronic liver disease 210
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 205
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 181
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 178
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 164
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 163
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 156
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 151
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 149
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 144
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease 144
Diabetes in chronic liver disease: from old concepts to new evidence 143
GH-resistance in different stages of chronic liver disease 142
[A 73-year-old woman with vomiting and metabolic alkalosis] 142
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 140
A challenging alfa-fetoprotein in a cirrhotic patient 139
[A 61-year-old woman with abdominal pain and urination disorders] 134
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 133
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 131
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 130
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 129
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 125
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 125
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 124
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 122
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 122
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 121
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 120
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 119
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 118
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 117
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 117
Pain and Frailty in Hospitalized Older Adults 114
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 112
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 107
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 105
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 103
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 101
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 100
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 99
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 99
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 97
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen 94
TNF-alpha and growth hormone resistance in patients with chronic liver disease 93
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 89
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 89
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures 87
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis 87
Reelin expression in human liver of patients with chronic hepatitis C infection 86
Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease 85
IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids 84
The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients 84
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 81
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 81
Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival 80
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables 80
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 80
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 79
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 79
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 79
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 78
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 77
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 77
The use of SAMe in chemotherapy-induced liver injury 74
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 74
Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease 73
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis 71
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 71
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 70
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population 69
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 68
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 68
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 68
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 68
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens 67
Severe hypophosphatemic osteomalacia secondary to fanconi syndrome due to adefovir: a case report 67
Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study 67
Totale 13.733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.138
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.138
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022326 0 0 0 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20267.065 620 332 457 810 255 354 1.755 409 534 665 432 442
2026/20272.372 135 728 944 565 0 0 0 0 0 0 0 0
Totale 18.902